REVIEW article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1633318
Decoding the Inflammatory-Osteogenic Axis in Ankylosing Spondylitis: Mechanisms, Dysregulation, and Emerging Therapeutic Interventions
Provisionally accepted- 1Jahangirnagar University, Savar, Bangladesh
- 2Hallym University, Chuncheon-si, Republic of Korea
- 3Kangwon National University, Chuncheonsi, Republic of Korea
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Ankylosing spondylitis (AS) is a chronic autoimmune disorder that primarily affects young people, with an incidence of approximately 1% worldwide. Although genetic and environmental factors have been implicated in the pathogenesis of AS, the etiology of this condition remains unclear. Observations indicate that individuals possessing the human leukocyte antigen (HLA)-B27 allele exhibit elevated risk factors, as any mutation within this gene could potentially result in the development of AS in the future. However, it is interesting to note that many AS patients do not carry this gene, inferring the involvement of other genetic and nongenetic factors in the development of the disease. As the exact mechanisms remain unknown, no target-specific treatments exist to cure AS. Nonetheless, some treatment regimens have been devised to alleviate AS symptoms. This review thoroughly examines the molecular mechanisms implicated in AS, encompassing insights into the significance of pivotal biomarkers, such as extracellular matrix metabolites, immune cell dynamics, gut microbiota interactions, the Wnt signaling pathway, and its inhibitors.Furthermore, a thorough evaluation of the different mouse models used in AS research has been reviewed, which is crucial for understanding disease pathways and assessing treatment methods. In addition, significant progress in developing effective treatment strategies for AS and drugs available for the treatment and in clinical trials for treating AS have, along with drugs available for treatment and ongoing clinical trials, has been summarized. A comprehensive understanding of experimental mice mouse models, along with insights into molecular mechanisms and biomarkers for AS, could aid researchers and physicians in discovering new treatment strategies for this challenging condition.
Keywords: ankylosing spondylitis, HLA-B27, PGISp mouse, ERAP1 gene, therapeutic targets
Received: 22 May 2025; Accepted: 22 Aug 2025.
Copyright: © 2025 Parvin, Sharma, Hasan, Sharma, Shawan, Seo, Hasan and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Md. Mahmudul Hasan, Jahangirnagar University, Savar, Bangladesh
Sang Soo Lee, Hallym University, Chuncheon-si, Republic of Korea
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.